Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$6.99 +9.9%	$5.61	$2.32 ▼ $10.13	$377.32M	2.4	955,072 shs	607,057 shs
HUMA Humacyte	$2.31 -2.1%	$2.00	$1.15 ▼ $9.79	$358.33M	1.99	3.82 million shs	2.64 million shs
KMDA Kamada	$7.20 -0.3%	$6.78	$4.83 ▼ $9.16	$414.07M	0.94	94,376 shs	55,533 shs
MGNX MacroGenics	$1.31 -4.4%	$1.52	$0.99 ▼ $5.77	$82.65M	1.66	825,475 shs	731,578 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	0.00%	+2.04%	+8.54%	+117.76%	+4.64%
HUMA Humacyte	0.00%	-2.53%	-8.70%	-30.42%	-55.32%
KMDA Kamada	0.00%	+4.65%	+8.60%	+1.41%	+50.63%
MGNX MacroGenics	0.00%	-13.82%	-13.25%	-33.16%	-70.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.1393 of 5 stars	1.3	0.0	0.0	0.0	2.5	0.0
HUMA Humacyte	2.1704 of 5 stars	3.5	1.0	0.0	1.9	2.5	0.6
KMDA Kamada	4.1491 of 5 stars	3.4	3.0	0.0	3.1	1.7	3.8
MGNX MacroGenics	3.6591 of 5 stars	3.2	1.0	4.4	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-10.08% Downside
HUMA Humacyte	3.00	Buy	$11.71	407.11% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	103.70% Upside
MGNX MacroGenics	2.40	Hold	$5.71	336.21% Upside

Current Analyst Ratings Breakdown

Latest MGNX, HUMA, KMDA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/14/2025	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	4.72	N/A	N/A	$4.51 per share	1.55
HUMA Humacyte	$1.57M	228.23	N/A	N/A	($0.41) per share	-5.63
KMDA Kamada	$160.95M	2.57	$0.49 per share	14.65	$4.51 per share	1.60
MGNX MacroGenics	$149.96M	0.55	N/A	N/A	$1.85 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)
KMDA Kamada	$14.46M	$0.29	24.83	22.50	0.87	9.60%	6.31%	4.43%	8/13/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)

Latest MGNX, HUMA, KMDA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/28/2025	Q4 2024	HUMA Humacyte	-$0.23	-$0.16	+$0.07	-$0.16	$0.64 million	$7.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	28.71	28.71
HUMA Humacyte	0.36	3.68	3.28
KMDA Kamada	N/A	3.30	1.93
MGNX MacroGenics	N/A	3.28	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
HUMA Humacyte	44.71%
KMDA Kamada	20.38%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
HUMA Humacyte	5.10%
KMDA Kamada	36.10%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable

MGNX, HUMA, KMDA, and FULC Headlines

Recent News About These Companies

MacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?

June 18, 2025 | marketbeat.com

MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead

June 16, 2025 | investing.com

MacroGenics lands $70M 'infusion of cash' to advance clinical programs

June 13, 2025 | bizjournals.com

MacroGenics: Working On That Road To Recovery

June 11, 2025 | seekingalpha.com

MacroGenics Shares Rise on Royalty-Purchase Agreement

June 10, 2025 | marketwatch.com

MacroGenics Target of Unusually Large Options Trading (NASDAQ:MGNX)

June 10, 2025 | marketbeat.com

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

June 10, 2025 | globenewswire.com

MacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to "Hold" Rating

June 7, 2025 | marketbeat.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Recommendation of "Hold" by Analysts

June 4, 2025 | marketbeat.com

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

June 3, 2025 | globenewswire.com

MacroGenics (NASDAQ:MGNX) Upgraded to Hold at Wall Street Zen

May 31, 2025 | marketbeat.com

Millennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

May 27, 2025 | marketbeat.com

MacroGenics (NASDAQ:MGNX) Lowered to "Sell" Rating by Wall Street Zen

May 24, 2025 | marketbeat.com

B. Riley Predicts MacroGenics' Q2 Earnings (NASDAQ:MGNX)

May 24, 2025 | marketbeat.com

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

May 23, 2025 | nasdaq.com

MacroGenics, Inc. (NASDAQ:MGNX) Holdings Lifted by Frazier Life Sciences Management L.P.

May 23, 2025 | marketbeat.com

4 Medical Product Stocks to Watch From a Challenging Industry

May 21, 2025 | zacks.com

6MGNX : 4 Analysts Assess Macrogenics: What You Need To Know

May 20, 2025 | benzinga.com

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 16, 2025 | finanznachrichten.de

Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50

May 16, 2025 | finance.yahoo.com

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

May 13, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, HUMA, KMDA, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$6.99 +0.63 (+9.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.00 +0.00 (+0.07%)

As of 06/20/2025 05:28 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Humacyte NASDAQ:HUMA

$2.31 -0.05 (-2.12%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.00 (+0.22%)

As of 06/20/2025 07:33 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Kamada NASDAQ:KMDA

$7.20 -0.02 (-0.28%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.05 -0.15 (-2.07%)

As of 06/20/2025 06:06 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

MacroGenics NASDAQ:MGNX

$1.31 -0.06 (-4.38%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.36 +0.05 (+3.82%)

As of 06/20/2025 07:57 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time